Accueil   Agenda - News   Toutes les news NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients.

NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients.

 

 

 

NH TherAguix (“NHT”), a clinical stage company developing innovative nanomedicines for the treatment of cancer, and the CHU Grenoble Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX, its candidate drug, with radiotherapy on multiple brain metastases patients, by Verry Camille et al., in Radiotherapy & Oncology medical journal.

 

his First-In-Man NANORAD trial led by the Grenoble Alpes University Hospital (principal investigator Dr. Camille Verry, Radiotherapy Department), allowed to assess favourably AGuIX in terms of tolerance after intravenous administration in combination with whole brain radiation therapy in patients with multiple brain metastases not suitable for stereotactic radiotherapy. Five dose levels (15, 30, 50, 75 and 100 mg/kg) have been successfully tested on 15 patients with a total of 354 brain metastases from 4 types of primary cancers (melanoma (n=6), lung cancer (n=6), colon cancer (n=1) and breast cancer (n=2). All patients have received one intravenous injection of AGuIX associated with a conventional whole brain radiation therapy (10 x 3 Gy).

 

Lire le communiqué de presse